CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2007-03-01): Baraclude treatment of HBV may induce HIV resistance

Regulatory

Baraclude treatment of HBV may induce HIV resistance

Last Updated: 2007-03-01 14:44:50 -0400 (Reuters Health)

NEW YORK (Reuters Health) - The US Food and Drug Administration has placed a warning on its MedWatch web site regarding a case report in which HIV developed a drug resistance mutation after the patient involved began treatment with entecavir (Baraclude) for co-infection with hepatitis B virus (HBV).

Bristol-Myers Squibb notified health care providers of this case and the company's change in recommendations. Its current treatment guidelines recommend entecavir as an option for the treatment of chronic HBV infection in individuals co-infected with HIV who are ineligible for HAART.

The company reports that the 31-year-old male discontinued treatment with antiretroviral agents in the year 2000. In early 2006, entecavir was prescribed for treatment of HBV. Prior to starting the drug, the patient's HIV-1 RNA level was 35,000 copies/mL, with no evidence of drug resistance.

Within 2 months, his HBV DNA decreased by approximately 5.5 log-10 IU/mL, and the HIV-1 RNA decreased to roughly 2,000 copies/mL. However, 6 months after initiating treatment with entecavir, HIV resistance testing revealed a M184V substitution.

As a result of this case, Bristol-Myers Squibb is changing its package insert.

Under section MICROBIOLOGY/Antiviral Activity, the company is adding the statement, "The EC50 value of entecavir against human immunodeficiency virus (HIV) type 1 laboratory strains NL4-3, BRU and LAI was > 1 micromolar in cell culture assays."

And under section INDICATIONS AND USAGE/Description of Clinical Studies/Special Populations, the instructions will read, "BARACLUDE has not been evaluated in HIV/HBV co-infected patients who were not simultaneously receiving effective HIV treatment."

In their letter, the company advises caution if Baraclude is used in HIV/HBV co-infected patients who are not being treated with HAART.

To obtain further information from Bristol-Myers Squibb regarding the appropriate use of entecavir or to report entecavir-related adverse events, providers can call 1-800-321-1335 or view the revised package insert online at www.baraclude.com.

Healthcare professionals are also encouraged to report entecavir-related adverse events to the FDA's MedWatch reporting program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, online at http://www.fda.gov/medwatch, or by mail to MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.